These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 18666246)

  • 21. Therapeutic potential of statins in Alzheimer's disease.
    Kandiah N; Feldman HH
    J Neurol Sci; 2009 Aug; 283(1-2):230-4. PubMed ID: 19321181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Declining frequency of liver enzyme abnormalities with statins: experience from general practice in Jerusalem.
    Kiderman A; Ben-Dov IZ; Glikberg F; Ackerman Z
    Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1002-5. PubMed ID: 18787468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical inquiries. Can patients with steatohepatitis take statins?
    Congdon D; St Anna L; Oh RC
    J Fam Pract; 2006 Oct; 55(10):905-6. PubMed ID: 17014759
    [No Abstract]   [Full Text] [Related]  

  • 24. The discovery of statins.
    Stossel TP
    Cell; 2008 Sep; 134(6):903-5. PubMed ID: 18805080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Statins with a perspective of lifelong therapy].
    Ertaş FS
    Turk Kardiyol Dern Ars; 2009 Mar; 37 Suppl 2():29-36. PubMed ID: 19404048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential for statins in the chemoprevention and management of hepatocellular carcinoma.
    Lonardo A; Loria P
    J Gastroenterol Hepatol; 2012 Nov; 27(11):1654-64. PubMed ID: 22849701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 'Muscle-sparing' statins: preclinical profiles and future clinical use.
    Pfefferkorn JA
    Curr Opin Investig Drugs; 2009 Mar; 10(3):245-52. PubMed ID: 19333882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The acute (cerebro)vascular effects of statins.
    Prinz V; Endres M
    Anesth Analg; 2009 Aug; 109(2):572-84. PubMed ID: 19608834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statins and the liver.
    Herrick C; Bahrainy S; Gill EA
    Cardiol Clin; 2015 May; 33(2):257-65. PubMed ID: 25939298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statins and hepatotoxicity: focus on patients with fatty liver.
    Chalasani N
    Hepatology; 2005 Apr; 41(4):690-5. PubMed ID: 15789367
    [No Abstract]   [Full Text] [Related]  

  • 31. The role of statin drugs in the management of the peripheral vascular patient.
    Samson RH
    Vasc Endovascular Surg; 2008; 42(4):352-66. PubMed ID: 18621887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An assessment by the Statin Liver Safety Task Force: 2014 update.
    Bays H; Cohen DE; Chalasani N; Harrison SA; The National Lipid Association's Statin Safety Task Force
    J Clin Lipidol; 2014; 8(3 Suppl):S47-57. PubMed ID: 24793441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rationale for the use of statins in liver disease.
    Schierwagen R; Uschner FE; Magdaleno F; Klein S; Trebicka J
    Am J Physiol Gastrointest Liver Physiol; 2017 May; 312(5):G407-G412. PubMed ID: 28280144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cholesterol, statins and cancer.
    Brown AJ
    Clin Exp Pharmacol Physiol; 2007 Mar; 34(3):135-41. PubMed ID: 17250629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statin and ezetimibe combination therapy in cardiovascular disease.
    Dembowski E; Davidson MH
    Curr Opin Endocrinol Diabetes Obes; 2009 Apr; 16(2):183-8. PubMed ID: 19262375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Statins: hepatotoxicity and monitoring].
    Cadranel JF; Seddik M; Loric S; Jeanne S
    Presse Med; 2009 May; 38(5):717-25. PubMed ID: 19111435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prescribing statins to patients with nonalcoholic fatty liver disease: real cardiovascular benefits outweigh theoretical hepatotoxic risk.
    Riley P; Al Bakir M; O'Donohue J; Crook M
    Cardiovasc Ther; 2009; 27(3):216-20. PubMed ID: 19555426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Possible role of adipocytokines in the development of nonalcoholic steatohepatitis-related hepatocellular carcinoma.
    Beyazit Y; Kekilli M; Purnak T; Kurt M
    Hepatology; 2010 Sep; 52(3):1172. PubMed ID: 20683933
    [No Abstract]   [Full Text] [Related]  

  • 39. Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy.
    Chehadeh W; Al-Nakib W
    J Med Virol; 2009 Apr; 81(4):610-8. PubMed ID: 19235842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic determinants of response to statins.
    Peters BJ; Klungel OH; de Boer A; Maitland-van der Zee AH
    Expert Rev Cardiovasc Ther; 2009 Aug; 7(8):977-83. PubMed ID: 19673675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.